Revenue Recognition - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended		33 Months Ended	66 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Prior period performance obligation revenue recognized			$ 200,000	$ (14,300,000)
Overpayment reimbursement liability	$ 21,400,000		21,400,000		$ 21,400,000	$ 21,400,000	$ 27,300,000
Revenue recognized					0
Total revenues	301,207,000	$ 226,368,000	512,674,000	448,820,000
Contract liability	17,700,000		17,700,000		$ 17,700,000	17,700,000	$ 21,800,000
Rayaldee
Disaggregation of Revenue [Line Items]
Revenue recognized	8,600,000	5,700,000	18,600,000	11,500,000
Total revenues	22,876,000		45,559,000
Transfer of intellectual property and other
Disaggregation of Revenue [Line Items]
Total revenues	20,880,000	19,230,000	30,433,000	37,490,000
Pfizer | Products
Disaggregation of Revenue [Line Items]
Revenue recognized						$ 0
Pfizer | Products | Transfer of intellectual property and other
Disaggregation of Revenue [Line Items]
Total revenues	13,900,000	$ 18,200,000	$ 22,700,000	$ 35,600,000
BioReference | Products | Transfer of intellectual property and other
Disaggregation of Revenue [Line Items]
Total revenues	$ 6,200,000